In summary, SMO and GLI1 genes are differentially expressed in malignant mesothelioma and benign mesothelioma tissues, which have more important guiding significance for the diagnosis and prognostic mechanism of mesothelioma and also open up new ideas for gene targeting and personalized immunotherapy of mesothelioma. This evidence concerns the gene SMO and benign mesothelioma.